Fewer than a tenth of people eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the World Health Organization as it publishes its first advice on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"Our new guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the treatments that can assist patients in reducing substantial body mass, notes the agency.
Skinny Jab Shortage
Even under the current most favorable case, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation urges countries and companies to expand availability, via measures like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is due to expire in multiple nations in 2026.
How Obesity Drugs Work
The injections mimick a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so individuals consume fewer calories.
Individuals commonly see weight reduction within a few weeks of commencing the weekly injections.
Research points to users may put most of the weight back on within a year of halting the medication, because their normal hunger resume.
Being overweight or obese elevates your risk for developing diseases, such as type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
